Choroidal Neovascularization - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Choroidal Neovascularization - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Choroidal Neovascularization - Pipeline Review, H1 2016', provides an overview of the Choroidal Neovascularization pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Choroidal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization
- The report reviews pipeline therapeutics for Choroidal Neovascularization by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Choroidal Neovascularization therapeutics and enlists all their major and minor projects
- The report assesses Choroidal Neovascularization therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Choroidal Neovascularization

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Choroidal Neovascularization Overview 7
Therapeutics Development 8
Pipeline Products for Choroidal Neovascularization - Overview 8
Pipeline Products for Choroidal Neovascularization - Comparative Analysis 9
Choroidal Neovascularization - Therapeutics under Development by Companies 10
Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes 11
Choroidal Neovascularization - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Choroidal Neovascularization - Products under Development by Companies 15
Choroidal Neovascularization - Products under Investigation by Universities/Institutes 16
Choroidal Neovascularization - Companies Involved in Therapeutics Development 17
Affitech A/S 17
F. Hoffmann-La Roche Ltd. 18
Genentech, Inc. 19
Iconic Therapeutics, Inc. 20
Mabion SA 21
Navigen Pharmaceuticals, Inc. 22
Noxxon Pharma AG 23
Promedior, Inc. 24
Sanwa Kagaku Kenkyusho Co., Ltd. 25
Choroidal Neovascularization - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AP-202 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Doxarubicin Pegylated - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
hI-con1 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
MAb-30D8 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NAV-2729 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Netrin-4 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
NM-9405 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NOXD-20 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PGN-635 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PRM-167 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ranibizumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ranibizumab biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
RG-7716 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
SK-1011 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Synthetic Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Choroidal Neovascularization - Recent Pipeline Updates 62
Choroidal Neovascularization - Dormant Projects 68
Choroidal Neovascularization - Discontinued Products 69
Choroidal Neovascularization - Product Development Milestones 70
Featured News & Press Releases 70
Nov 26, 2013: NICE gives green light to ranibizumab for eye condition in final guidance 70
Jul 05, 2013: Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization 70
May 31, 2013: Novartis Receives Positive CHMP Opinion For Lucentis To Treat Myopic Choroidal Neovascularization Showing Vision Gains With Only Two Injections 71
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables

Number of Products under Development for Choroidal Neovascularization, H1 2016 8
Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Choroidal Neovascularization - Pipeline by Affitech A/S, H1 2016 17
Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 18
Choroidal Neovascularization - Pipeline by Genentech, Inc., H1 2016 19
Choroidal Neovascularization - Pipeline by Iconic Therapeutics, Inc., H1 2016 20
Choroidal Neovascularization - Pipeline by Mabion SA, H1 2016 21
Choroidal Neovascularization - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 22
Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H1 2016 23
Choroidal Neovascularization - Pipeline by Promedior, Inc., H1 2016 24
Choroidal Neovascularization - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Stage and Target, H1 2016 28
Number of Products by Stage and Mechanism of Action, H1 2016 30
Number of Products by Stage and Route of Administration, H1 2016 32
Number of Products by Stage and Molecule Type, H1 2016 34
Choroidal Neovascularization Therapeutics - Recent Pipeline Updates, H1 2016 62
Choroidal Neovascularization - Dormant Projects, H1 2016 68
Choroidal Neovascularization - Discontinued Products, H1 2016 69